Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Carl Shanholtz"'
Autor:
Jean A. Yared, Elizabeth Hutnick, Ashraf Badros, Mehmet H. Kocoglu, Nancy M. Hardy, Forat Lutfi, Søren M. Bentzen, Jonathan Siglin, Aaron P. Rapoport, Firas El Chaer, Carl Shanholtz, Kathleen Ruehle, Vivek Kesari, Noa G. Holtzman, Hao Xie, Haroon Ahmad, Saurabh Dahiya, Ali Bukhari, Natalie Gahres
Publikováno v:
Neuro Oncol
Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associat
Autor:
Wesley H. Self, Thomas G. Stewart, Allison P. Wheeler, Wissam El Atrouni, Amanda J. Bistran-Hall, Jonathan D. Casey, Vince D. Cataldo, James D. Chappell, Claudia S. Cohn, Jessica B. Collins, Mark R. Denison, Marjolein de Wit, Sheri L. Dixon, Abhijit Duggal, Terri L. Edwards, Magali J. Fontaine, Adit A. Ginde, Michelle S. Harkins, Thelma Harrington, Estelle S. Harris, Daanish Hoda, Tina S. Ipe, Stuti J. Jaiswal, Nicholas J. Johnson, Alan E. Jones, Maryrose Laguio-Vila, Christopher J. Lindsell, Jason Mallada, Manoj J. Mammen, Ryan A. Metcalf, Elizabeth A. Middleton, Simon Mucha, Hollis R. O’Neal, Sonal R. Pannu, Jill M. Pulley, Xian Qiao, Jay S. Raval, Jillian P. Rhoads, Harry Schrager, Carl Shanholtz, Nathan I. Shapiro, Stephen J. Schrantz, Isaac Thomsen, Krista K. Vermillion, Gordon R. Bernard, Todd W. Rice, For the Passive Immunity Trial for Our Nation (PassITON) Investigators
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-13 (2021)
Trials
Research Square
article-version (status) pre
article-version (number) 1
Trials
Research Square
article-version (status) pre
article-version (number) 1
Background Convalescent plasma is being used widely as a treatment for coronavirus disease 2019 (COVID-19). However, the clinical efficacy of COVID-19 convalescent plasma is unclear. Methods The Passive Immunity Trial for Our Nation (PassITON) is a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497ca2964f35cfb2ca2977ed143f398c
https://doi.org/10.21203/rs.3.rs-227796/v1
https://doi.org/10.21203/rs.3.rs-227796/v1
Publikováno v:
Journal of Critical Care. 38:73-77
Purpose Pandemic influenza A pdm09 (pH1N1) virus was the predominant isolate identified during the 2009-10 and 2013-14 influenza outbreaks, causing significant morbidity and mortality. We describe clinical characteristics of critically ill patients d
Autor:
Peter J. Pronovost, Dale M. Needham, O. Joseph Bienvenu, Pedro A. Mendez-Tellez, Cheryl Dennison-Himmelfarb, Carl Shanholtz, Elizabeth Colantuoni
Publikováno v:
Critical Care Medicine. 43:642-653
To evaluate the cooccurrence, and predictors of remission, of general anxiety, depression, and posttraumatic stress disorder symptoms during 2-year follow-up in survivors of acute lung injury treated in an ICU.Prospective cohort study, with follow-up
Autor:
Dale M. Needham, Oscar J. Bienvenu, Benjamin M. Althouse, Jonathan Gellar, Carl Shanholtz, C. R. Dennison, Pedro A. Mendez-Tellez, Elizabeth Colantuoni, T. Sricharoenchai, Peter J. Pronovost
Publikováno v:
Psychological Medicine. 43:2657-2671
BackgroundSurvivors of critical illnesses often have clinically significant post-traumatic stress disorder (PTSD) symptoms. This study describes the 2-year prevalence and duration of PTSD symptoms after acute lung injury (ALI), and examines patient b
Autor:
Carl Shanholtz, Xinggang Liu, Ann M. Parker, Anthony D. Harris, Dean R. Hess, Giora Netzer, Robin L Smith, Marty Reynolds
Publikováno v:
Respiratory Care. 58:438-449
The effect of the respiratory therapist (RT)/patient ratio and RT organizational factors on respiratory resource utilization is unknown. We describe the impact of a multi-component intervention that called for an increase in RT/patient ratio (1:14 to
Publikováno v:
Annals of Pharmacotherapy. 44:1529-1537
Background: Rasburicase is indicated for the initial management of plasma uric acid levels in adults receiving anticancer therapy who are at risk for acute tumor lysis syndrome (TLS) and subsequent hyperuricemia. The labeled dose is 0.2 mg/kg/day adm
Autor:
Abdulla A. Damluji, Jonathan E. Sevransky, Carl Shanholtz, Joel E. Gallant, Pedro A. Mendez-Tellez, Elizabeth Colantuoni, Eddy Fan, Dale M. Needham, Douglas Ammerman, Peter J. Pronovost
Publikováno v:
Critical Care Medicine. 38:1530-1535
Objective: To evaluate the impact of human immunodeficiency virus infection on hospital mortality in patients with acute lung injury and to evaluate predictors of mortality among acute lung injury patients with human immunodeficiency virus. Design, S
Autor:
David J. Murphy, Carl Shanholtz, Bennett B. Edelman, Michael L. Terrin, Anthony D. Harris, Xinggang Liu, Giora Netzer, John R. Hess
Publikováno v:
Transfusion. 50:2125-2134
BACKGROUND: Clinical guidelines recommend a restrictive transfusion strategy in nonhemorrhaging critically ill patients. STUDY DESIGN AND METHODS: We conducted a retrospective observational study of 3533 single-admission patients, without evidence of
Autor:
David W. Dowdy, Pedro A. Mendez-Tellez, Dale M. Needham, Oscar J. Bienvenu, Victor D. Dinglas, Jonathan E. Sevransky, Carl Shanholtz
Publikováno v:
Critical Care Medicine. 37:1702-1707
To evaluate intensive care-related factors as predictors of depressive symptoms 6 months after acute lung injury (ALI).Prospective cohort study.Thirteen intensive care units (ICUs) in four hospitals in Baltimore, MD.Consecutive ALI survivors (n = 160